The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Biliary Atresia: Clinical and Research Challenges for the Twenty‐First Century
Open accessAbstract
Biliary atresia (BA) is a fibroinflammatory disease of the intrahepatic and extrahepatic biliary tree. Surgical hepatic portoenterostomy (HPE) may restore bile drainage, but progression of the intrahepatic disease results in complications of portal hypertension and advanced cirrhosis in most children. Recognizing that further progress in the field is unlikely without a better understanding of the underlying cause(s) and pathogenesis of the disease, the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored a research workshop focused on innovative and promising approaches and on identifying future areas of research. Investigators discussed recent advances using gestational ultrasound and results of newborn BA screening with serum direct (conjugated) bilirubin that support a prenatal onset of biliary injury. Experimental and human studies implicate the toxic properties of environmental toxins (e.g., biliatresone) and of viruses (e.g., cytomegalovirus) to the biliary system. Among host factors, sequence variants in genes related to biliary development and ciliopathies, a notable lack of a cholangiocyte glycocalyx and of submucosal collagen bundles in the neonatal extrahepatic bile ducts, and an innate proinflammatory bias of the neonatal immune system contribute to an increased susceptibility to damage and obstruction following epithelial injury. These advances form the foundation for a future research agenda focused on identifying the environmental and host factor(s) that cause BA, the potential use of population screening, studies of the mechanisms of prominent fibrosis in young infants, determinations of clinical surrogates of disease progression, and the design of clinical trials that target subgroups of patients with initial drainage following HPE. (H epatology 2018; 00:000‐000).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wen, J., Zhou, Y., Wang, J., Chen, J., Yan, W., Wu, J. S., Yan, J., Zhou, K., Xiao, Y., Wang, Y., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.31 · Cited by 31
RetractedVascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“These include bile acid–based therapeutics such as the farnesoid X receptor (FXR) agonist obeticholic acid in primary biliary cholangitis and the modified bile acid norursodeoxycholic acid, which is currently in phase 2 trials in adult primary sclerosing cholangitis.(46,47) FXR agonists suppress bile acid synthesis an…”
BackgroundHartley, J. L., Davenport, M., & Kelly, D. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60946-6 · Cited by 877
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
Self-citationSerinet, M., Wildhaber, B. E., Broué, P., et al. (2009) · PEDIATRICS · doi:10.1542/peds.2008-1949 · Cited by 463
Hohenester, S., de Buy Wenniger, L. M., Paulusma, C. C., van Vliet, S. J., Jefferson, D. M., Oude Elferink, R. P., & Beuers, U. (2012) · Hepatology · doi:10.1002/hep.24691 · Cited by 315
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.009 · Cited by 297
Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes
Asai, A., Miethke, A., & Bezerra, J. A. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.74 · Cited by 279
Self-citation
Cited by
Bile Acids as Metabolic Regulators and Nutrient Sensors
Chiang, J. Y. L., & Ferrell, J. M. (2019) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124344 · Cited by 437
The role of vitamin D and vitamin D binding protein in chronic liver diseases
Pop, T. L., Sîrbe, C., Benţa, G., Mititelu, A., & Grama, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810705 · Cited by 105
“Most patients had progressive liver fibrosis despite the hepatic portoenterostomy (HPE) and evolved toward cirrhosis and end-stage liver disease with the need for liver transplantation (LT) [40].”
BackgroundBiliary organoids uncover delayed epithelial development and barrier function in biliary atresia
Amarachintha, S. P., Mourya, R., Ayabe, H., Yang, L., Luo, Z., Li, X., Thanekar, U., Shivakumar, P., & Bezerra, J. A. (2022) · Hepatology · doi:10.1002/hep.32107 · Cited by 98
Self-citationLiver organoids: established tools for disease modeling and drug development
Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000105 · Cited by 37
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Metadata
- Authors
- Bezerra, J. A., Wells, R. G., Mack, C. L., Karpen, S. J., Hoofnagle, J. H., Doo, E., & Sokol, R. J.
- Venue
- Hepatology
- Published
- 2018-09
- Volume
- 68
- Issue
- 3
- Pages
- 1163-1173
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2794632001
- Cited by
- 343
- References
- 49
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biliary Atresia: Clinical and Research Challenges for the Twenty‐First Century. https://app.cochat.ai/papers/10.1002/hep.29905
- The paper
- Bezerra, J. A., Wells, R. G., Mack, C. L., Karpen, S. J., Hoofnagle, J. H., Doo, E., & Sokol, R. J. (2018). Biliary Atresia: Clinical and Research Challenges for the Twenty‐First Century. Hepatology. https://doi.org/10.1002/hep.29905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.